Masy Pharma

Masy Pharma has been active since 1986 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €475,544 and a net result of €5,768. Equity remains stable across the filed financial years (±0.9% per year). Its solvency ranks better than 80% of 12,678 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).